Latest:
HealthcarePress Releases

Circulating Biomarkers Market Size to Reach USD 14.22 Billion by 2034, Growing at a CAGR of 11.90%

Rohan 113 Views 6 min read

The global circulating biomarkers market is poised for robust growth, with its value projected to rise from USD 5.17 billion in 2025 to an impressive USD 14.22 billion by 2034. This expands at a healthy compound annual growth rate (CAGR) of 11.90%, driven by rising chronic disease diagnostics, personalized medicine demand, early detection needs, and advanced healthcare infrastructure investments.

Circulating Biomarkers Market Size 2025 to 2034

What Are Circulating Biomarkers and Why Are They Gaining Momentum?

Circulating biomarkers are biological molecules found in bodily fluids such as blood, urine, or saliva, providing critical insights into health and disease states. These include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), extracellular vesicles (EVs), proteins, and metabolites. Their minimally invasive nature allows earlier disease diagnosis, ongoing monitoring, and targeted treatment, especially pivotal in cancer and chronic conditions.

Circulating Biomarkers Market Key Highlights

  • The market size stood at USD 5.17 billion in 2025 and is forecast to reach USD 14.22 billion by 2034, growing at 11.90% CAGR.

  • North America dominated the market in 2024, while the Asia Pacific region is set to be the fastest-growing between 2025 and 2034.

  • Circulating DNA was the leading biomarker type by market share in 2024, with circulating tumor cells exhibiting swift growth prospects.

  • The hospital segment accounted for the largest application share in 2024; however, medical research centers are among the fastest-growing application sectors.

Role of Artificial Intelligence in Circulating Biomarkers

Artificial intelligence (AI) has become a transformative force in circulating biomarker analysis, enabling precise diagnostics and personalized treatment optimization. AI algorithms analyze complex high-throughput data such as from next-generation sequencing and mass spectrometry, identifying novel biomarker signatures efficiently.

AI-powered liquid biopsies can detect minimal residual disease (MRD) by analyzing ctDNA early, allowing for timely therapy adaptations. Advances like PanGIA Biotech’s AI-integrated urine-based liquid biopsy for prostate cancer exemplify AI’s commercialization impact, accelerating detection and reducing invasiveness.

Circulating Biomarkers Market Scope

Report Coverage Details
Market Size in 2025 USD 5.17 Billion
Market Size in 2026 USD 5.78 Billion
Market Size by 2034 USD 14.22 Billion
Market Growth Rate from 2025 to 2034 CAGR of 11.90%
Dominating Region North America
Fastest Growing Region Asia Pacific

What Are the Major Growth Drivers in This Circulating Biomarkers Market ?

The circulating biomarkers market is fueled by an increasing prevalence of cancer and chronic diseases worldwide, which demands early and non-invasive diagnostic methods. Regulatory approvals are rising, facilitating market expansion.

Technological advancements in high-throughput and liquid biopsy platforms enhance detection capabilities. Growing healthcare infrastructure and intensified research funding globally create a supportive ecosystem for market players. Furthermore, personalized medicine’s rising importance elevates the need for circulating biomarkers in therapeutic decisions.

What Opportunities and Trends Are Shaping the Circulating Biomarkers Market?

How are liquid biopsies advancing cancer detection and care?
Liquid biopsies represent a minimally invasive alternative to traditional biopsies, enabling continual monitoring of tumor genetics and treatment response. This facilitates personalized therapeutic approaches and improved patient outcomes.

Which emerging technologies hold promise for biomarker detection?
Microfluidics, AI, and novel assays are propelling sensitivity and specificity improvements for biomarker detection. Chip technology advances allow better circulating tumor cell capture and analysis, while epigenetic tests expand early cancer detection.

How are geographic dynamics influencing growth prospects?
North America’s leadership is underpinned by substantial R&D investment and regulatory support. Meanwhile, Asia Pacific’s rapidly developing infrastructure and increasing chronic disease burden position it as the fastest-growing regional market.

Challenges and Cost Pressures

Despite promising growth, the market faces challenges including high development and validation costs, stringent regulatory pathways, and the need for standardization in biomarker assays. Cost pressures may limit accessibility and adoption, especially in emerging regions. Additionally, integrating complex AI tools requires significant infrastructure and expertise, posing short-term barriers.

Circulating Biomarkers Market Regional and Segmentation Insights

North America emerged as the largest market in 2024 due to advanced healthcare infrastructure, significant cancer prevalence, a wealth of regulatory approvals, and high R&D expenditures.

The U.S. drives this dominance with modern healthcare institutions and growing personalized medicine adoption. In contrast, Asia Pacific is forecast as the fastest-growing region, driven by healthcare infrastructure development, rising burden of diseases, and increasing R&D investment.

By biomarker type, circulating DNA dominates, closely followed by rapidly growing circulating tumor cells.

Application-wise, hospitals currently lead, driven by liquid biopsy adoption and precision medicine, while medical research centers exhibit significant growth potential.

Latest Breakthroughs from Leading Companies

Significant innovations from top companies propel market momentum:

  • Guardant Health’s FDA-approved Shield blood test for colorectal cancer screening.

  • PanGIA Biotech’s AI-integrated urine-based prostate cancer liquid biopsy launched in India.

  • Mercy BioAnalytics received FDA Breakthrough Device Designation for its ovarian cancer screening test.

  • Myriad Genetics advanced molecular residual disease tests for renal cell carcinoma.

Circulating Biomarkers Market Key Companies

  • Abbott Laboratories

  • Becton, Dickinson and Company (BD)

  • GE Healthcare

  • Epigenomics AG

  • Agilent Technologies

  • Biocept

  • Affymetrix (Thermo Fisher Scientific)

  • Fluxion Biosciences

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7055

You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344

Rohan
Rohan
Principal Consultant at Market Stats Insight
Rohan Patil is a seasoned Healthcare Principal Consultant at Market Stats Insight and Precedence Research, with more than 5 years of experience in market intelligence and strategic insights. Holding a BSc in Biotechnology and an MBA in Marketing, he combines scientific expertise with business acumen to deliver data-driven analysis. Rohan specializes in the medical device sector and closely tracks innovations shaping the future of healthcare. His research helps global clients identify growth opportunities, assess risks, and stay competitive in a rapidly evolving market landscape.
Rohan
Latest posts by Rohan (see all)

Rohan

Rohan Patil is a seasoned Healthcare Principal Consultant at Market Stats Insight and Precedence Research, with more than 5 years of experience in market intelligence and strategic insights. Holding a BSc in Biotechnology and an MBA in Marketing, he combines scientific expertise with business acumen to deliver data-driven analysis. Rohan specializes in the medical device sector and closely tracks innovations shaping the future of healthcare. His research helps global clients identify growth opportunities, assess risks, and stay competitive in a rapidly evolving market landscape.